Intranasal vaccination with messenger RNA as a new approach in gene therapy: Use against tuberculosis by Lorenzi, Julio CC et al.
RESEARCH ARTICLE Open Access
Intranasal vaccination with messenger RNA as a
new approach in gene therapy: Use against
tuberculosis
Julio CC Lorenzi
1, Ana PF Trombone
1, Carolina D Rocha
1, Luciana P Almeida
1, Ricardo L Lousada
1,
Thiago Malardo
1, Isabela C Fontoura
1, Renata AM Rossetti
1, Ana F Gembre
1, Aristóbolo M Silva
2, Celio L Silva
1,
Arlete AM Coelho-Castelo
1*
Abstract
Background: mRNAs are highly versatile, non-toxic molecules that are easy to produce and store, which can allow
transient protein expression in all cell types. The safety aspects of mRNA-based treatments in gene therapy make
this molecule one of the most promising active components of therapeutic or prophylactic methods. The use of
mRNA as strategy for the stimulation of the immune system has been used mainly in current strategies for the
cancer treatment but until now no one tested this molecule as vaccine for infectious disease.
Results: We produce messenger RNA of Hsp65 protein from Mycobacterium leprae and show that vaccination of
mice with a single dose of 10 μg of naked mRNA-Hsp65 through intranasal route was able to induce protection
against subsequent challenge with virulent strain of Mycobacterium tuberculosis. Moreover it was shown that this
immunization was associated with specific production of IL-10 and TNF-alpha in spleen. In order to determine if
antigen presenting cells (APCs) present in the lung are capable of capture the mRNA, labeled mRNA-Hsp65 was
administered by intranasal route and lung APCs were analyzed by flow cytometry. These experiments showed that
after 30 minutes until 8 hours the populations of CD11c
+, CD11b
+ and CD19
+ cells were able to capture the
mRNA. We also demonstrated in vitro that mRNA-Hsp65 leads nitric oxide (NO) production through Toll-like
receptor 7 (TLR7).
Conclusions: Taken together, our results showed a novel and efficient strategy to control experimental
tuberculosis, besides opening novel perspectives for the use of mRNA in vaccines against infectious diseases and
clarifying the mechanisms involved in the disease protection we noticed as well.
Background
The use of mRNA to encode a protein as a vehicle in
gene therapy was extensively used in cancer research
[1]. This method relies on the in vitro transfection of
mRNA into autologous dendritic cells (DCs) that are re-
administered to the patient. It has shown good efficiency
in terms of induction of T-cell responses in cancer
patients, but presented several drawbacks including cost,
limited number of cells/vaccine doses, and the intrinsic
phenotypic variability of the in vitro generated DCs.
Moreover, the ideal maturation state and delivery
modalities of transfected DCs are still matter of debate.
As an alternative, mRNA could be used in naked form.
Direct injection of mRNA coding for immune domi-
nants antigens could lead a strong immune response
against the encoded antigen, as demonstrated in cancer
models [2,3]. Recently, Weid [4] concluded the second
phase 1/2 vaccination trial in metastatic melanoma
patients. Using mRNA from six different immune domi-
nant antigens from melanoma he showed that after vac-
cination patients developed important CD4
+ immune
response. One important feature of naked mRNA is the
ability of fast activation of the innate immune system by
pathways such as Toll like receptors (TLRs) [5], RIG 1
and MDA5 [6]. Moreover, the action of the translated
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in the induction of specific immune response.
Tuberculosis (TB) causes more than 2 million deaths
per year all over the word [7]. Currently the only avail-
able tuberculosis vaccine is Mycobacterium bovis bacil-
lus Calmette-Guerìn (BCG), but its effectiveness varies,
particularly against the adult pulmonary form of the dis-
ease [8]. The increasing incidence of AIDS, long chemi-
cal treatments and the emergence of multidrug resistant
strains are compelling evidences for the urgency of new
therapeutic strategies against TB [9]. Since its first
description in March, 2006 [10], resistance has become
the most alarming issue in international tuberculosis
control and might be responsible for compromising the
progress observed in many countries over the last dec-
ade [11].
Many studies of subunit vaccines have been underta-
ken by using different antigens, such as Ag85 complex
[12], 38 kDa protein [13], 19 kDa protein [14], RD1
region [15] and Ag85B-ESAT-6 complex [16]. It has
been reported that 65 kDa heat shock protein (Hsp65)
is one of the major immune reactive proteins during the
Mycobacterium tuberculosis (MTB) infection. Addition-
ally, the immunity induced by DNA vaccines encoding
M. leprae Hsp65 (DNA-Hsp65) can reduce the bacterial
loads in spleen and lung of the infected mice after intra-
muscular injection [17,18]. The immunity induced by
Hsp65 reflects mainly in the production of Th1 cyto-
kines mostly IFN-gamma [19]. Moreover, it was well
demonstrated that DNA vaccines encoding MTB Hsp65,
initially designed to prevent infection, also had a pro-
nounced therapeutic effect, which could eliminate the
bacteria in TB mice after antibacterial chemotherapy
[20]. The antigens cited above have already been tested
using plasmid DNA constructs. Once plasmid DNA is
the major contributor in the TB vaccine list, some issues
concerning security, like the possibility of DNA integra-
tion and autoimmunity, cann o tb ea s s u r e d[ 2 1 ] .I nt h i s
way, the development of a new strategy based on mes-
senger RNA (mRNA) can be an attractive approach. We
show here that one intranasal dose of 10 μgo fm R N A
coding for Hsp65 protein from M. leprae leads to an
immune response that protects mice against M. tubercu-
losis infection.
Results
Expression profile of mRNA-Hsp65 produced in vitro
The first step in the protocol of the mRNA vaccine was
to evaluate if the mRNA production had been success-
ful. As shown in figure 1(A), the purified mRNA-Hsp65
and EF-1a mRNA showed a fragment of 1,800-bp (lane
1) and 1,850-bp (lane 2), respectively, which matched
the expected length. When the mRNA-Hsp65 and the
control mRNA were treated with RNAse A, no fragment
was observed (data not shown), confirming the homoge-
neity of the mRNA preparation. In order to verify the
presence of possible sites that could inhibit the transla-
tion of mRNA-Hsp65, we also determined the RNA-
Hsp65 predicted structure using Mfold web based
software[22] (Additional file 1). These analyses showed
that mRNA-Hsp65 did not have significant loops or
arms that could interrupt the translation process.
To determine if mRNA-Hsp65 could be translated in
mammalian cells, we first detected mRNA and protein
in mRNA-Hsp65-transfected HEK293T cells. The Figure
1(B) RT-PCR and 1(C) western-blot confirms the
mRNA stability and the Hsp65 protein expression in
HEK293T cells at various time points after the mRNA
uptake by these cells. After 30 minutes, 2 and 4 hours
of the incubation we detected mRNA-Hsp65 by RT-
PCR (Figure 1B). Presumably mRNA was consumed or
degraded by the cell metabolism after 8 hours from the
inoculation of the mRNA, as observed by the lack of
intensity of gel fragment. The protein expression was
observed after 30 minutes of inoculation with mRNA-
Hsp65 and persisted until 12 hours later (Figure 1C,
densitometry in Additional file 2). These results con-
firmed that mRNA-Hsp65 is stable inside mammalian
cells and could be translated in Hsp65 protein.
Lung antigen presenting cells (APCs) can uptake mRNA-
Hsp65 in vivo after intranasal immunization
Once mRNA was captured and translated in vitro,w e
evaluated if mRNA-Hsp65 could be uptaken by mam-
malian cells in vivo. To test this hypothesis, mice were
intranasally immunized with tagged mRNA-Hsp65.
After different time points lung cells were analyzed by
flow cytometry. From 30 minutes until 4 hours post-
immunization we observed that dendritic cells were the
majority of cells that had uptaken the mRNA-Hsp65
when compared with macrophages and B cells. Four
hours after the immunization around 25% of dendritic
cells were positive for the tagged mRNA (Figure 2).
Besides the uptake by classical APCs we do not detected
non APCs cells marked for tagged mRNA-Hsp65 (Addi-
tional file 3). Taken together these data confirmed that
intranasal route could be used for mRNA vaccine strat-
egy, since these molecules were able to reach lung
APCs.
Vaccination with mRNA-Hsp65 induces protection against
tuberculosis
In order to verify if mRNA-Hsp65 vaccination strategy
works in vivo, we tested this strategy in tuberculosis
experimental model. Thus, we challenged mice by intra-
nasal route with virulent M. tuberculosis H37Rv 30 days
after immunization with the 10 or 5 μgo fm R N A -
Hsp65 or control EF-1a mRNA or BCG. Four weeks
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in the lungs were quantified by CFU protocol. Only
mice that were immunized with 10 μg of mRNA-Hsp65,
showed a significant decrease of bacterial count when
compared with the mRNA control or the RL control
group (p < 0.05) (Figure 3). The BCG group was used as
a positive protection control. Histological lung sections
from infected mice were analyzed to determine the
development and the presence of the inflammatory infil-
trates. As shown in figure 4, mice treated with 10 μg
mRNA-Hsp65 vaccine (panel 6) or BCG (panel 2)
showed almost intact alveolar tissue. On the other hand,
there was considerable infiltration of mononuclear cells
and extensive parenchyma destruction evidenced by
large and poorly demarcated granuloma in the lungs
from the control mice immunized only with 5 or 10 μg
of EF-1a mRNA (panel 3 and 4).
Immunization with mRNA-Hsp65 induces production of
IL-10 and TNF-alpha cytokines
Cytokines play an important role in the immune
response to M. tuberculosis, since it was demonstrate
that vaccination with mRNA-Hsp65 induces protection
against tuberculosis we explore if the immunization
with mRNA-Hsp65 generated specific Th1 cytokine pro-
duction. We observed that immunization with 10 μgo f
naked mRNA-Hsp65 induced a specific and significant
increase of IFN-gamma (figure 5A) and TNF-alpha (fig-
ure 5B) compared to RL control group. Concanavalin A
(ConA) stimulation was used as control. Cytokine pro-
duction obtained with ConA was shown in Additional
file 4.
mRNA-Hsp65 stimulation lead NO production via Toll like
Receptor 7
Once it was shown that mRNA-Hsp65 could induce
protection against M. tuberculosis challenged in vivo,w e
explored if this effect could be started by TLR7 activa-
tion. Thus, HEK293T cells were transfected with TLR 7
and exposed to mRNA-Hsp65 in vitro.M e a s u r i n gN O
release from these cells, we showed that mRNA-Hsp65
stimulates the production of this molecule significantly
via TLR 7 receptor (Figure 6).
Discussion
We showed here that one dose of 10 μgo fn a k e d
mRNA encoding M. leprae Hsp65 was enough to pro-
tect mice against M. tuberculosis infection. We also
showed that this naked mRNA stimulated Th1specific
cytokine production and was efficiently captured by
Figure 1 (A) - Electrophoretic profile of in vitro synthesized
messenger RNAs. Lane M: 0.5-10 kb RNA Ladder (Invitrogen), lane
1: 1 μg of mRNA-Hsp65, 2: 1 μg of EF-1a mRNA. The
electrophoresis was performed in 1.5% denaturing agarose gel
stained with ethidium bromide. (BP-Base pair, M-Marker). (B) -
Detection of the integrity of the mRNA-Hsp65 by RT-PCR. After
transfection of HEK 293 cells with the mRNA-Hsp65 cells were
maintained in culture for different periods of time, as showed in the
figure, in order to analyze the presence of mRNA-Hsp65.
Electrophoresis was run in 1.5% agarose gel and stained with
ethidium bromide (NC-Negative PCR control, NT-Not transfected,
PC-Positive PCR control). (C) - After contact mRNA-Hsp65 for
different periods of time, the total cell lysate was subjected to
polyacrylamide gel electrophoresis (12.5%) and the bands
transferred to nitrocellulose membrane and incubated with anti-
Hsp65 for 2 hours. The reaction was revealed with secondary
antibody anti-mouse IgG in the presence of DAB. (RC-Recombinant
protein Hsp65, NT-Not transfected)
Figure 2 Assessment of the amount of professional antigen-
presenting cells capable of capturing mRNA-Hsp65 labeled
with Alexa488. Five BALB/c mice per group were immunized by
intranasal route with one dose of 10 μg of Alexa488 labeled mRNA-
Hsp65. The control group received Ringer’s solution. The kinetics of
the capture was made in different times (indicated in the legend)
and the cellular phenotype detected by flow cytometry. Data
represent the mean positive cell counts ± SD of five mice per
group of one of three independent experiments
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mainly by dendritic cells and. Moreover we detected
activation of TLR7 pathway via mRNA-Hsp65.
T h eu s eo fn a k e dm R N Aa sav e h i c l ef o rg e n et h e r a p y
has increasing in the last few years. The majority of the
studies used mRNA transfected in dendritic cells and
were focused on the stimulation of CD8
+ cytotoxic T
lymphocyte response, as well as on the induction of CD4
+ T helper cell response, in order to obtain optimal and
sustained immune responses capable of eliminating
tumor cells [23]. Although the use of naked mRNA was
more restricted to cancer research until now, in this
report we showed that it is possible to use naked mRNA
intranasally against a pulmonary disease. This mRNA can
pass through all nasal and tracheal barriers and reach the
l u n g s ,w h e r et h e yc a nb ec a p t u red by different APCs. In
our approach we used an mRNA from M. leprae Hsp65,
which has already been extensively evaluated as an
experimental tuberculosis vaccine, an mRNA capable of
being translated into transfected mammalian cells. In
HEK 293T cells transfected with mRNA-Hsp65 the pro-
tein expression was observed since the early 2 hours of
the delivery of the mRNA, until 12 hours after transfec-
tion. These results showed that any possible differences
in protein expression of prokaryotic system like codon
bias [24] did not suppress the expression of M. leprae
protein in mammalian system. Also, mRNA-Hsp65 was
stable and ready for expression in mammalian system,
suggesting that the formulated vaccine mRNA can be
kept inside HEK 293T cells until its translation. Besides,
we used bioinformatics tools to show that produced
mRNA-Hsp65 had a minimum structure that would not
interfere in the translation process, since this parameter
is very important to initiate the protein production [25].
We also confirmed that once the mRNA was inside
the cell, the translation process could be done, with the
production of Hsp65 30 minutes after the transfection
process (Figure 1C). This result could explain the func-
tionality of the vaccination, once we observed protein
production and protection against M. tuberculosis infec-
tion in mice. In addition, the induction of specific
immune response against the mRNA encoding antigen,
c a na l s ob eu s e f u li ng e n et h e r a p yb e c a u s et h i sk i n do f
mRNA have some structural characteristics that confer
the ability to activate APCs [26].
After the translation process, the produced protein
can enter in the class I pathway of immunologic presen-
tation process for activation of CD8
+ T cells or partici-
pate of cross-priming process for CD4
+ T cells [27]. The
mRNA performs this activation process and in the max-
imum of 8, 12 hours disappears of the system. This
interesting characteristic differs from other gene therapy
vehicles such as plasmid DNA vaccines that can be res-
cued in the in vivo system after 6 months of immuniza-
tion [28]. In addition to mRNA stability, we showed the
uptake of this mRNA by lung APCs, mainly dendritic
cells, after the intranasal immunization, suggesting that
transfected dendritic cells may induce a protective
immune response. The activation state of these cells was
critical in the tuberculosis infection since macrophages
and dendritic cells can stop the infection in the early
stages, if stimulated. Moreover after the immunization
this APCs can stimulate specific T cells, creating mem-
ory T cells [29].
The CFU counting and histopathology analysis showed
that 10 μg of mRNA-Hsp65 given by the intranasal route
can reduce the bacterial load and inflammation in mice
lungs. When we compared the CFU results from mice
immunized with the control mRNA containing the
mRNA-Hsp65 group it is possible to reaffirm that Hsp65
is a vaccine antigen, since the control mRNA group
neither decreased the bacterial load nor improved the lung
inflammation as compared with RL group. We speculated
that only innate cellular activation provided by the control
mRNA was not able to protect mice against tuberculosis.
The protection that we obtained in our experiments
was very motivating since we used only one dose of 10
μg of mRNA-Hsp65 by the intranasal route, contrasting
Figure 3 Intranasal vaccination with mRNA-Hsp65 protects
mice against tuberculosis. Five BALB/c mice per group were
immunized by intranasal route with a dose of different formulations
containing mRNA-Hsp65 or EF-1a mRNA. BCG group received
subcutaneously 1 dose of BCG Moreau. Non vaccinated group
received only the Ringer’s solution. Thirty days after the last
immunization, animals were challenged with 10
5 bacilli of the
virulent H37Rv strain of M. tuberculosis by intranasal route. Thirty
days after challenge, animals were euthanized and their lungs
extracted for the evaluation of the bacterial load. Data represent the
mean log10 CFU counts ± SD of five mice per group of one of
three independent experiments. *p < 0.05 were considered
significant when compared to non vaccinated group.
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Page 4 of 11Figure 4 Histological analysis of lungs of BALB/c mice vaccinated and challenged with virulent strain of Mycobacterium tuberculosis.
Five BALB/c mice per group were immunized by intranasal route with a dose of different formulations containing mRNA-Hsp65 or EF-1a mRNA.
The BCG group received 1 dose of BCG Moreau subcutaneously. Thirty days after the last immunization animals were challenged with 10
5 bacilli
of the virulent strain of M. tuberculosis by H37RV intranasal route. Thirty days after challenge, animals were sacrificed and their lungs extracted for
the recovery histology. 1-Non vaccinated group, 2-BCG group, 3-EF-1a mRNA 5 ug group, 4-EF-1a mRNA 10 μg group, 5-mRNA-Hsp65 5 ug
group, 6-mRNA-Hsp65 10 μg group. Staining was performed with hematoxylin and eosin (HE), increased original image of 100×.
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muscular route in the original research [18] passing by
prime-boost [30] and recently with entrapment of plas-
mid DNA in cationic vesicles reduce to an single dose
of 25 ug of plasmid by the intranasal route [31]. Besides,
we used a needle free immunization, intranasal, which
has a great advantage in the development of a TB vac-
cine since the nasal associated lymphoid tissue partici-
pate in the initiation and modulation of immune
response against pulmonary infections [32].
Moreover we showed that immunization with mRNA-
Hsp65 could induce specifically production of Th1 cyto-
kines IFN-gamma and TNF-alpha. IFN-gamma are
essential for the development of protective immunity
against TB [33,34] and is probably the most important
factor that activates macrophages antimycobacterial
action, at least in TB response [19,35]. The importance
of TNF-alpha in TB improved since the discovery of
reactivation of dormant TB in patients using TNF-neu-
tralizing drugs [36,37]. From these studies the role of
T N Fi nt h ef o r m a t i o no fg r a n u l o m aw a sd e m o n s t r a t e d
[37]. TNF-alpha blockage impair the antimicrobial activ-
ity of memory CD8
+ T cells by reducing the production
of perforin and granulysin the major components of
CD8
+ T antimicrobial response to intracellular patho-
gens [38]. Thus the mRNA approach could induces a
TH1 pattern like DNA vaccines.
Furthermore the presence of important cytokines after
mRNA-Hsp65 immunization, driven by the expression
of Hsp65 protein, we asked if this mRNA molecule
could induce intracellular activation via toll like receptor
7. Through in vitro experiments we showed that
Figure 5 Immunostimulatory activity of mRNA-Hsp65.F i v e
BALB/c mice per group mice were immunized with one dose of
mRNA-Hsp65 (10 μg per mouse in 100 μL volume). Not immunized
group received only the Ringer’s solution. Two weeks after the
immunization splenic cells are isolated and stimulated with 20 μg/
ml of Hsp65 protein, 48 hours after stimulation the production of
(A) IFN-gamma and (B) TNF-alpha by were determined by ELISA.
*p < 0.05 were considered significant when compared to not
immunized group.
Figure 6 TLR7 activation by hsp65 mRNA. HEK293T cells (3 × 10
5
cells/well) were co-transfected in triplicate with the TLR expression
plasmids. The next day, cells were treated with hsp65 mRNA or
following TLRs agonists: poly-IC 100 μg/ml (TLR3), LPS 1 μg/ml (O55:
B55) (TLR4) and R-848 1 μg/ml (TLR7 and 8) for 7 hours. The
amount of NO release was measured form culture supernatant
using the method of Griess. Data are presented as the means ± SD
of triplicate cultures. *p < 0.05 were considered significant when
compared to empty vector.
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NO, an antimicrobrial molecule that is induced by TLR
[39]. The activation via TLR7 culminates in NF-KB
expression leading production of inflammatory cyto-
kines. This process could occur simultaneously with the
Hsp65 protein production, which may be considered a
potent co-stimulatory event that enhances the immune
activation of Hsp65 protein.
In the last two decades, tuberculosis incidence chan-
ged from a disease exclusive of poor countries into a
worldwide illness. This change becomes visible with the
presence of multi-resistance and extreme resistant
strains of M. tuberculosis all over the word [40]. Thus,
the search for a new vaccine against TB became a very
important issue. But until now the only available vaccine
is BCG that has been extensively used, but is not always
effective. Our group has worked on the development of
a tuberculosis vaccine using different approaches that
could deliver a well know and effective antigen to the
immune system [41].
Thus, the use of mRNA as a vaccine or in treatments
seems to be highly effective. This promising mRNA
immunization was approved to the first human treat-
ment trial protocol, in which intradermal injections of
CV9103 stable mRNA was used against metastatic pros-
tate cancer as well as another strategy using mRNA
from tumor as an immune activator [42]. Pascolo and
others showed the feasibility and safety of this protocol
in humans [43]. These two examples demonstrate that
the use of mRNA in gene therapy seems to be one of
the easiest, most versatile and theoretically safest tech-
nologies in this field. Our results open a perspective to
use of this strategy in other infectious disease models
with a cost effective when compared with other systems.
Conclusion
The mRNA based vaccination protocol described here,
showed that one immunization with of 10 μgo fH s p 6 5
mRNA administered by the intranasal route could lead
suppression of experimental tuberculosis in mice. Since
our approach use low dose of a non toxical molecule,
delivered by a needle free immunization and is able to
establish protection against tuberculosis, it opens a new
perspective in gene therapy and can be used in other
diseases since is safety, fast and easy to made.
Methods
Plasmids
Plasmid pcDNA3A-Hsp65 contained T7 RNA Polymer-
ase promoter and cDNA encoding the gene for M.
Leprae Hsp65 that has been previously described [20].
Plasmid DNA was purified as described in Endo-Free
QIAGEN plasmid purification kit (QIAGEN AG, Basel,
Switzerland). Spectrophotometry analysis revealed 260/
2 8 0n mr a t i o so f1 . 8 0o rm o r e .T h ep u r i t yo ft h eD N A
was confirmed in a 1% agarose gel. Plasmid concentra-
tion was determined by spectrophotometry at the wave
lengths 260 and 280 nm using Nanodrop ND-1000
(NanoDrop Technologies, Wilmington, USA).
mRNA preparation
Plasmids containing the full length cDNA of Hsp65
gene (pcDNA3A-Hsp65) were linearized with APA I
enzyme and purified at a final concentration of 1 μg/μL
by standard protocols. Plasmid pTRI-Xef, used as a con-
trol template containing 1.85-kbp elongation factor 1-a
gene from Xenopus laevis (EF-1a), was already linear-
ized by Ambion (Austin, Texas, USA). RNA replicons
were in vitro transcribed using linearized replicon plas-
mids and mMessage mMachine Ultra Kit (Ambion),
according to the manufacturer’s recommendations. After
the RNA synthesis was complete, the in vitro transcrip-
tion reactions were treated with RNase-free DNase
(Ambion) at 37°C for 15 min to degrade the DNA tem-
plates. The next step was the synthesis of poly-A tail,
and then the RNA was purified by acidic phenol/chloro-
form extraction followed by mRNA isopropanol precipi-
tation. mRNAs were quantified by absorbance at 260
and 280 nm using Nanodrop (Thermo), and the propor-
tion of full-length transcripts was checked by formalde-
hyde denaturing agarose gel electrophoresis. All
formulations were tested for endotoxin levels with QCL-
1000 Limulus amebocyte lysate. The levels found were
under 0.01 EU/mL.
mRNA structure analysis
Plasmid pcDNA3A-Hsp65 template (data not shown)
was sequenced to assure that the sequences required to
the perfect translation process were present. Since the
plasmid had all these sequences, in silico mRNA struc-
ture analysis was performed using mFOLD default
parameters.
Cell assay
Transfections was made in HEK 293T cells with mRNA-
Hsp65 were made using Transmessenger Transfection
Reagent (Qiagen), according to the manufacturer’s
instructions. Briefly, 10 μgo fm R N A - H s p 6 5p r o d u c e d
in vitro was mixed with Transmessenger Reagent for 1
hour and then applied to a 70% confluent culture of
HEK 293T cells maintained in Dulbecco’s modified
Eagle’s medium (DMEM) (Gibco-BRL, Gaithersburg,
USA) without serum. After 30 minutes, 2, 4, and 8
hours, total RNA was extracted using Trizol (Invitrogen,
Carlsbad, USA), according to the manufacturer’s
recommendation.
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Total cellular RNA (10 μg/mL) was reverse transcribed
using oligo(dT) primers and Superscript reverse tran-
scriptase (Invitrogen), according to the manufacturer’s
recommendations. The contaminating plasmid DNA
was removed by treatment with DNAse I, amplification-
grade (Invitrogen). The sequences of PCR primers for
the amplification of Hsp cDNA were 5’-ACC AAC GAT
GGC GTG TCC AT-3’ (sense) and 5’-TAG AAG GCA
CAG TCG AGG-3’ (antisense), resulting in a 400-bp
PCR product. Primers for b-actin were used as a control
for the quantity of RNA used. b-actin specific primers
amplified a 450-bp product and were composed of the
following sequences: 5’-GTG GGC CGC TCT AGG
CAC CAA-3’ (sense) and 5’-CTC TTT GAT GTC ACG
CAC GAT TTC-3’ (antisense). All primers were pur-
chased from Invitrogen. The cDNA (2 μg) was sub-
mitted to an initial denaturation step (95°C, 5 minutes),
followed by 35 cycles of denaturation (94°C, 30 sec-
onds), annealing (60°C, 45 seconds), and extension
(72°C, 1.5 minute), and a final extension step (72°C, 3
min). PCR amplification products were analyzed by
agarose gel 1% electrophoresis and stained with ethi-
dium bromide. In order to avoid cross-contamination,
all procedures including the PCR, were performed in
separate laminar flow hoods.
Western Blot
Total protein content from transfected HEK 293T cells
was extracted 30 minutes, 2, 4, and 8 hours after the
mRNA transfection using RIPA buffer. The Hsp65 poly-
clonal antibody and the Hsp65 recombinant protein
used in this blot were kindly provided by Dr. Célio
Lopes Silva. The total protein extract was separated by
SDS-PAGE and transferred to nitrocellulose membranes.
Membranes were incubated with blocker solution [(3%
BSA (w/v) in PBS containing 0.05% Tween-20 (v/v)
(PBS-T)] for 2 hours at 37°C, followed by a incubation
with mouse polyclonal anti-Hsp65 IgG for 18 hours at
4°C. After washing with PBS-T, the membranes were
incubated with goat anti-mouse IgG peroxidase conju-
gate (Invitrogen). Reactions were revealed by DAB Sub-
strate Kit for peroxidase (Vector, London, UK).
mRNA uptake experiments
mRNA labeling
mRNA encoding full-length Hsp65 gene was labeled
with Alexa Fluor 488 by Universal Linkage System (ULS
(tm)) using the ULYSIS nucleic acid labeling kit (Mole-
cular Probe Inc, Eugene, USA) with some modifications.
Briefly, mRNA (10 μg) was incubated in labeling buffer
(25 μL) and denatured at 95°C for 5 min and cooled on
ice. The ULS labeling reagent stock solution (2 μL) was
a d d e dt ot h et u b ea n dt h er e a c t i o ni n c u b a t e da t8 0 ° C
for 15 min. The labeled mRNA was purified by ethanol
precipitation, followed by suspension in Ringer Lactate
solution (RL).
Mice and labeled mRNA immunization
BALB/c mice, 6 to 8 weeks old, were obtained from the
Animal Facilities of the Medical School of Ribeirão
Preto, University of São Paulo, and were maintained
under standard laboratory conditions. The Alexa 488
labeled mRNA (10 μg per mouse in 100 μL volume) for-
mulated in RL was given by intranasal route with 50 μL
in each nostril. Control mice were immunized with the
same dose of unlabeled mRNA. All experiments were
approved and conducted in accordance with the guide-
lines of the Animal Care Committee of the University.
Preparation of lung cells
Lungs were washed with sterile PBS and each was
placed in a Petri dish containing incomplete RPMI-1640
medium (Sigma). Lungs were fragmented and trans-
ferred to a conical tube containing digestion solution,
prepared with Liberase Blendzyme 2 (Roche, Indianapo-
lis, IN) diluted (0·5 μg/ml) in incomplete RPMI-1640.
Samples were incubated at 37° under agitation for 30
min After incubation, the cells were dispersed by using
a 10-ml syringe and pelleted by centrifugation for 10
min at 400 g. Cells were then washed with complete
RPMI-1640, passed through a Nytex screen (Sigma) and
resuspended in complete RPMI-1640. Total cell counts
were determined in a Neubauer chamber.
FACS analysis
Single-cell suspensions (1 × 10
6)i s o l a t e df r o ml u n g so f
i m m u n i z e dm i c eo b t a i n e d3 0m i n u t e s ,2 ,4a n d8
hours after the injection of labeled mRNA were sus-
pended in RPMI 1640 medium (Life Technologies,
Grand Island, NY). After lysis of red blood cells
(RBCs) with ACK buffer, cells were pre-incubated with
anti-CD16/32 (FcBlock - 2.4G2) monoclonal antibodies
(mAb) to block FcgR, and then incubated with the
mAb anti-CD19
+ (PE), anti-CD11b
+ (PerCP) and anti-
CD11c
+ (APC) for 30 min at 4°C (all antibodies were
purchased from Becton Dickinson, San Diego, USA).
Mice immunized with unlabeled mRNA were used as a
control. Analytical flow cytometry was carried out
using a FACSCANTO II (Becton Dickinson, San Jose,
USA) and the data were processed using the FACS-
DIVA software (Becton Dickinson). A biparametric
gate was drawn around the mononuclear populations
in the forward (FSC) and side (SSC) scatter dot plot.
The gated populations were then selected according to
CD19
+, CD11b
+, or CD11c
+ staining. Alexa488 positive
population was considered after background analysis
from appropriate isotype controls. All antibodies were
purchased from BD (BD PharMingen, San Diego,
USA). The gating strategy was shown on Additional
file 5.
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Animals
Female 6-week-old BALB/c mice were obtained from
the Animal Facilities of the Medical School of Ribeirão
Preto, University of São Paulo. All experiments were
approved and conducted in accordance with the guide-
lines of the Animal Care Committee of the University.
Infected animals were kept in biohazard facility of the
Level 3 Biosafety Laboratory and housed in cages within
a laminar flow safety enclosure under standard
conditions.
Immunization procedures
Immunization was performed by the following treatments,
using five animals per group. For BCG immunization, one
dose of Moreau strain was given by subcutaneous injection
of 10
5 live bacteria in 100 μL of saline. For mRNA vaccina-
tion the mRNA-Hsp65 (10 or 5 μg per mouse in 100 μL
volume) was formulated in RL and given by intranasal
route with 50 μL drop in each nostril. EF-1a mRNA was
given by the same process and formulations. For cytokine
evaluation mice were immunized with one dose of
mRNA-Hsp65 (10 μg per mouse in 100 μLv o l u m e )w a s
formulated in RL and given by intranasal route with 50 μL
drop in each nostril, as control we immunize mice only
with Ringer solution.
Experimental infection with M. tuberculosis
The H37Rv strain of M. tuberculosis (American Type
Culture Collection, Rockville, MD) was grown in 7H9
Middlebrook broth (Difco Laboratories, Detroit, USA)
for seven days. The culture was harvested through centri-
fugation and the cell pellet was resuspended in sterile
phosphate buffered saline (PBS) and vigorously agitated.
The homogeneous suspension was filtered through 2 μm
filters (Millipore, Bedford, MA). Viability of the M. tuber-
culosis suspension was pre-tested with fluorescent diace-
tate (Sigma, Saint Louis, MO) and ethidium bromide at
least 80% viable. Thirty days after mRNA immunization
all mice groups were challenged with M. tuberculosis.
Intranasal challenge was made by introducing 1×10
5
viable CFU of M. tuberculosis H37Rv in 100 μL of PBS by
50 μL drop in each nostril. Control mice received PBS.
Mice from all groups were euthanized on day 30 after
infection and their lungs were aseptically removed. Lungs
from each mouse were used for histopathology analyses
and quantification of the bacterial loads.
Determination of M. tuberculosis CFU in lungs
The number of live bacteria was determined by extract-
ing the right lobes of the lung, washed with sterile PBS,
followed by plating 10-fold serial dilutions of homoge-
nized tissue on Middlebrook 7H11 agar media (Difco)
[supplemented with 0.2% (v/v) glycerol and 10% (v/v)
bovine fetal serum], and counting colonies after 28 days
at 37°C. The colony-forming units (CFU) are expressed
as log10 of CFU/g lung.
Histology
30 days post-infection, the left lobe of each mouse lung
was removed and fixed in 10% formalin. Paraffin blocks
were prepared and then sectioned for light microscopy.
Sections (5 μm each) were stained with hematoxylin &
eosin (HE). Slides were evaluated using a Leitz Model
Aristoplan microscope (Germany) connected to a Leica
Model DFC280 color camera (Heerbrugg, Germany)
linked to a PC computer.
Evaluation of cytokine production
Two weeks after mRNA-Hsp65 immunization the ani-
mals were sacrificed and splenic cells were collected and
adjusted to 5 × 10
6 cells/ml in RPMI 1640 medium,
supplemented with 5% FCS, 20 mM glutamine and 40
IU/l of gentamicin. The cells were cultured in 48-well
flat-bottomed culture plates (Nunc, Life Tech. Inc.,
Maryland, MA, US) in the presence of 20 μg/ml of Con-
canavalin A (ConA) or Hsp65 recombinant protein.
Cytokine levels in culture supernatants were evaluated
48 hours later by ELISA. Cytokines were measured fol-
lowing manufacturer instructions (PharMingen). Purified
monoclonal antibodies anti-IFN-g (R4-6A2) and anti-
TNF-alpha (G281-2626) were used at 1 μg/ml as capture
antibodies and the following biotinylated antibodies
were used for detection: anti-IFN-g (XMG1.2) and anti-
TNF-alpha (MP6-XT3) at 0,5 μg/ml.
In vitro TLR 7 assay
Cell Culture, plasmids and transfection. HEK293T cells
were grown in DMEM with 10% fetal bovine serum, sup-
plemented with penicillin and streptomycin. All transfec-
tions were performed in 24-well plates. One day before
transfection, cells were plated at 3 × 10
5 cells/well. Cells
were transfected with pcDNA3.1 (1 μg/well) as empty
vector or the TLRs plasmids (1 μg/well), All TLR vectors
was kindly provided by Dr. Aristóbolo Mendes da Silva.
The next day cells were left untreated or treated with
hsp65 mRNA (2, 5 or 10 μg/ml) or agonists specific for
each TLR for 7 h before harvest. The following TLRs
agonists were used: poly-IC 100 μg/ml (TLR3), LPS 1 μg/
ml (O55:B55) (TLR4) and R-848 1 μg/ml (TLR7 and 8).
Nitrite, the end product of NO metabolism, was mea-
sured from 50 μlo fc e l lc u l t u r es u p e r n a t a n t sb yu s i n g
Griess reagent, as described elsewhere [44]
Statistical analysis
All values are expressed as mean±SEM. Data were
investigated by analysis of variance (anova) using graph-
pad instat software. When the values indicated the pre-
sence of a significant difference, a Tukey-Kramer
multiple comparisons test was used. Values of P <0 · 0 5
were considered significant.
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Additional file 1: mRNA-Hsp65 structure. The sequence of Hsp65 ORF
plus their 3’ UTR region was modeled in Mfold software. This model
shows that this mRNA do not have any structural obstacle that can
inhibit the translation process.
Additional file 2: Hsp65 expression after mRNA uptake. After contact
mRNA-Hsp65 for different periods of time, the total cell lysate was
subjected to polyacrylamide gel electrophoresis (12.5%) and the bands
transferred to nitrocellulose membrane and incubated with anti-Hsp65
for 2 hours. The reaction was revealed with secondary antibody anti-
mouse IgG in the presence of DAB. The blot was scanned and
densitometry analysis was performed using NIH Image J Software. The
different time points were shown in the graph.
Additional file 3: Assessment of the amount of non professional
antigen-presenting cells (APCs) capable of capturing mRNA-Hsp65
labeled with Alexa488. Five BALB/c mice per group were immunized
by intranasal route with one dose of 10 μg of Alexa488 labeled mRNA-
Hsp65. The control group received Ringer’s solution. Lung cells were
obtained and prepared for flow citometry analysis. The strategy to non
APCs was: First of all we make a gating profile that select only the non
CD11C, CD11B and CD19 cells, from these cells we make a histogram
that measures the alexa 488 positive cells. It is possible to see that non
APCs do not capture Alexa488 labeled mRNA-Hsp65.
Additional file 4: Gating strategy. The cytometry procedure was made
to exclude the auto fluorescence and include only Alexa 488 cells. (A).
Dot plots for control isotypes on (CD11c
+, CD11b
+ and CD19
+)a n d
histogram examples gating on Alexa 488 (B). Dot plots for positive cells
on (CD11c
+, CD11b
+ and CD19
+) and histogram for positive cells on
Alexa 488.
Additional file 5: Immunostimulatory activity of mRNA-Hsp65. Five
BALB/c mice per group mice were immunized with one dose of mRNA-
Hsp65 (10 μg per mouse in 100 μL volume) as control we immunize
mice only with Ringer solution. Two weeks later the immunization
splenic cells are isolated and stimulated with 20 μg/ml A Concanavalin,
48 hours after stimulation the production of (A) IFN-gamma and (B) TNF-
alpha by were determined by ELISA.
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